Skip to Content

A Phase I, open-label, multicenter, dose escalation study of oral BGJ398, a pan FGFR kinase inhibitor, in adult patients with advanced solid malignancies

Objective
Clinical trial of investigational drug BGJ398 given by mouth.
IRB Protocol Number
09-1156
Principal Investigator(s)
ROSS CAMIDGE

Cancer Trials

  • All Cancers
Sponsor(s)
Novartis
Contact
SARAH RIPPKE at 720-848-0685
or RIPPKE.SARAH@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last as long as you are responding well to the study drug. A follow up period will consist of a clinic visit after you stop taking the study drug (to follow for any lasting side effects). // Eligibility criteria include but are not limited to 18 years or older with advanced solid tumor(s).

Location

  • Clinical Translational Research Center (CTRC)